SCHEMBL11567282

SCHEMBL11567282

Cc1ccc(N(C)Cc2ccccc2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HTT P42858 1/20 0.47
TP53 P04637 1/20 0.45
CYP2C19 P33261 1/20 0.44
ALDH1A1 P00352 4/20 0.44
PKM P14618 1/20 0.43
MEN1 O00255 1/20 0.43
ATM Q13315 1/20 0.43
ERAP1 Q9NZ08 1/20 0.43
NTRK1 P04629 1/20 0.41
NTRK3 Q16288 1/20 0.41
NTRK2 Q16620 1/20 0.41
AOC3 Q16853 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11564050 0.89 LMNA (0.43) GAAMAPTSMN1; SMN2TSHRKMT2A
SCHEMBL15075696 0.84 CYP2C19 (0.55) GAASMN1; SMN2TSHRKMT2ALMNA
SCHEMBL11568099 0.83 KDM4E (0.41) GAASMN1; SMN2TSHRKMT2ALMNA
SCHEMBL11564788 0.83 PKM (0.62) SMN1; SMN2KMT2ALMNAKDM4EALDH1A1
SCHEMBL11564474 0.82 HCAR3 (0.54) GAAMAPTSMN1; SMN2KMT2AKDM4E
SCHEMBL11566621 0.81 PKM (0.52) SMN1; SMN2KMT2ALMNAALDH1A1PKM
SCHEMBL11563183 0.81 ALDH1A1 (0.48) MAPTSMN1; SMN2TSHRKMT2ALMNA
SCHEMBL27303499 0.80 GAA (0.47) GAAMAPTSMN1; SMN2TSHRKMT2A
SCHEMBL11561492 0.80 PKM (0.51) SMN1; SMN2PKMAOC3
SCHEMBL11566524 0.79 LMNA (0.36) GAAMAPTSMN1; SMN2TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783522-B2 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-10-10 US disclosed
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-16 US disclosed
EP-0000816-A1 Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1979-02-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF ENPP2, ATXN2, ATXN2L GAA 277/4885MAPT 1937/4885SMN1; SMN2 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.